Gentronix entered into a three-year agreement to provide GlaxoSmithKline (GSK) with GreenScreen HC and BlueScreen HC genotoxicity assays. The reporter-based assays have demonstrated the ability to detect known classes of genotoxic agent and utilize Green Fluorescent Protein or Gaussia Luciferase to detect GADD-45a upregulation, which is a key indicator of DNA damage.
GreenScreen HC is a human cell-based assay technology that combines high sensitivity for detecting genotoxic chemicals with high specificity for reducing false positive results, Gentronix notes. BlueScreen HC is the new luciferase-based assay that combines all the attributes of GreenScreen HC with the ability to be run in a 384-well microtiter plate format.
